David Henry's JCSO Podcast

In the final JCSO podcast for 2017, Dr David Henry, the Editor-in-Chief, discusses a round-up by Dr Linda Bosserman of cancer care in 2017 and an accompanying article on the therapeutic implications of some of the year’s landmark approvals. Continuing with the theme of therapeutic advances, he also highlights a review of the expanding treatment options for diverse neuroendocrine tumors. Two articles, one on setting up systems to facilitate adoption of the oncology care model in the practice setting and another on the clinical presentation, diagnosis, and management of bronchopulmonary carcinoid, provide evidence-based information and guidelines for practice-based oncology care teams. Patient and survivor care are the focus of three original research reports in which authors report on supportive medications and interventions received by prostate cancer survivors (PiCTure study); differences in psychosocial stressors between black and white cancer patients; and the impact of combining human and online supportive resources for prostate cancer patients. Also discussed are case reports on metastatic eccrine carcinoma with stomach and pericardial involvement and on cold hemolytic anemia as a rare complication of influenza A, as well as the approvals of pembrolizumab for dMMR/MSI-H tumors and brigatinib for crizotinib-resistant, ALK-positive NSCLC patients.

JCSO Podcast sept oct 2017 by David Henry

JCSO Interview Anderson With Music by David Henry

For the July-August issue of the Journal of Community and Supportive Oncology, the Editor-in-Chief, Dr David Henry, discusses a recap by Howard Burris, MD, of the top presentations at this year’s annual meeting of the American Society for Clinical Oncology, and a selection of articles on some of the key findings reported at the meeting. A number of articles, in keeping with the journal mission of delivering content that can inform or change daily practice in the community setting, provide ‘how-to’ clinical and supportive advice. They include an outline by Thomas J Smith of Johns Hopkins University of how to initiate goals-of-care conversations with patients and their family members; a review of managing polycythemia vera in the community oncology setting; a New Therapies feature on how immunotherapies are shaping the treatment of hematologic malignancies; and research articles on using Onodera’s Prognostic Nutritional Index to predict wound complications in patients with soft tissue sarcoma, and bone remodeling associated with CTLA-4 inhibition. A third research article assesses a multidisciplinary survivorship program in a group of predominantly Hispanic women with breast cancer. Also in the line-up for discussion are Case Reports, one on managing high-grade pleomorphic sarcoma in a patient with colon metastasis and another on intramedullary spinal cord and leptomeningeal metastases presenting as cauda equina syndrome in a patient with melanoma.

For the May-June issue of the Journal of Community and Supportive Oncology, the Editor in Chief, Dr David Henry, discusses an editorial by Kevin Knopf, a JCSO editor, about drawing on modern portfolio theory to improve cancer care. Side effects come under scrutiny this issue, with a How We Do It article on prehabilitation for lymphedema in head and neck cancer patients, a Review article that examines pancreatitis associated with newer classes of antineoplastic therapies, and a research article that looks at prescriber adherence to antiemetic guidelines with trifluridine-tipiracil. In other research articles, investigators report on physician attitudes and prevalence of molecular testing in lung cancer; a comprehensive assessment of cancer survivors’ concerns to inform program development; and perceived financial hardship among patients with advanced cancer. Two Case Reports address the treatment of Kaposi sarcoma in patients with AIDS, and a third describes a rare case of hypoglycemia induced by a classic gastrointestinal stromal tumor. Finally, Dr Henry summarizes an in-depth interview on cardiotoxicity, which he did with his colleague, Dr Joseph Carver.

JCSO June Podcast - Cardiotoxicity Carver

For the March-April issue of the Journal of Community and Supportive Oncology, the Editor in Chief, Dr David Henry, discusses two informative “how-to” articles, one on the implementation of a distress management program at an oncology hospital in Puerto Rico, the other on the prevention and treatment options for mTOR inhibitor-associated stomatitis. Dr Henry also shares his preferences for addressing health care reform, and he highlights a letter to the journal in response to the January-February issue Commentary on physician-assisted dying. Immunotherapies are at the fore again, this time with an insightful essay by Jane de Lartigue who writes that combination therapy is likely to be key in expanding the scope of immunotherapy into currently unresponsive patient populations, which raises questions about the optimal combinations and the timing and sequencing of combination immunotherapy. Three Original Reports span the clinical, supportive, and quality- and value-based care components of cancer care, with their respective foci on APF530 for nausea and vomiting prevention after cisplatin; patterns of care in whole-brain radiotherapy technique and delivery; and emergency department use by newly diagnosed cancer patients. As usual, there is a line-up of rare and challenging presentations in Case Reports on pulmonary sarcomatoid carcinoma presenting as a necrotizing cavitary lung lesions, palmoplantar exacerbation of psoriasis after nivolumab for lung cancer, primary cardiac prosthetic valve-associated lymphoma; and atraumatic splenic rupture as an initial presentation of chronic myelogenous leukemia.

In his April podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry discusses Original Reports on olanzapine compared with fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting and an analysis of patient-reported outcomes in prostate cancer after treatment with abiraterone acetate. Also among the line-up of Original Reports are studies looking at the diagnostic work-up for the detection of malnutrition in hospitalized cancer patients and at the use of video-conferencing to deliver cancer genetic counseling to high-risk underserved individuals. The Case Reports include an unusual case of non-small-cell lung cancer presenting as spontaneous cardiac tamponade, another of severe eosinophilia associated with cholangiocarcinoma, and a third on acute benzodiazepine toxicity exacerbated by concomitant oral olanzapine. The Community Translations column features approvals of nivolumab approval for metastatic renal-cell carcinoma. Dr Henry also discusses a feature article on new therapies for multiple myeloma that are redefining the condition as a chronic disease.

In David Henry’s March podcast for The Journal of Community and Supportive Oncology, he discusses a number of articles that center on patient quality of life and overall quality of care, among them, an article on opioid risk assessment in palliative care and three Original Reports, one on the impact of trimodality treatment on arm function and QoL in patients with superior sulcus tumors, a second on patient perceptions and the challenges of oral anticancer therapy, and a third on the use of voluntary reporting to assess symptom burden in cancer patients. A Review article by Jose de Souza and colleagues on financial toxicity in cancer care spans the QoL and quality of care spectrum as it details the implications of the increasing cost of cancer care for the delivery of high-quality, patient-centered care and discusses potential predictors of financial toxicity and instruments that could help quantify financial burden. Also in the line-up are articles on encapsulated irinotecan for hard-to-treat cancer and Case Reports on an uncommon presentation of lung cancer and on acute promyelocytic leukemia presenting as a paraspinal mass.

For the February podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry examines two Original Reports, one on a collaborative investigation by scientists and members of a social network into fluoroquinolone-related neuropsychiatric and mitochondrial toxicity and another on the prognostic value of complete remission with superior platelet counts in patients with acute myeloid leukemia. The Case Reports this month focus on rare tumors: in one case, it is a metastatic primary bladder adenocarcinoma for which a novel treatment approach prolonged survival; and in a second, an 18-year follow-up on a rare, indolent form of T-cell prolymphocytic leukemia. The Community Translations column features the novel MEK inhibitor, cobimetinib, which was approved last year in combination with the BRAF inhibitor, vemurafenib, for metastatic melanoma with BRAF V600E or V600K mutation. Dr Henry also discusses articles on new therapies for gastrointestinal cancers and on selected practice-changing presentations from the 2015 annual meeting of the San Antonio Breast Cancer Symposium in Orlando last year.